12.86
前日終値:
$11.64
開ける:
$11.93
24時間の取引高:
138.05K
Relative Volume:
1.88
時価総額:
$632.97M
収益:
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-7.15%
1か月 パフォーマンス:
-20.17%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
Agomab Therapeutics Nv Adr Stock (AGMB) Company Profile
Compare AGMB vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
AGMB
Agomab Therapeutics Nv Adr
|
12.86 | 573.16M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
|
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Agomab Therapeutics Nv Adr Stock (AGMB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-03 | 開始されました | JP Morgan | Overweight |
| 2026-03-03 | 開始されました | Leerink Partners | Outperform |
| 2026-03-03 | 開始されました | Morgan Stanley | Overweight |
Agomab Therapeutics Nv Adr (AGMB) 最新ニュース
Total equity of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total liabilities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total liabilities & shareholders' equities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total debt of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Balance Sheet – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Cash Flow – DUS:M5E - TradingView
EBITDA per share of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Income Statement – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Earnings and Revenue – DUS:M5E - TradingView
Basic earnings per share (basic EPS) of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Free float of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm
Total common shares outstanding of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Tangible book value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Debt to assets ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Cash per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Net current asset value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Enterprise value to EBITDA ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
EBITDA margin % of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Cash Flow – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Balance Sheet – TRADEGATE:M5E - TradingView
EBITDA of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Diluted earnings per share (diluted EPS) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Non-operating income (total) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Financial Statements – TRADEGATE:M5E - TradingView
Diluted net income available to common stockholders of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Revenue Breakdown – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Statistics – TRADEGATE:M5E - TradingView
Gross profit of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Net income before discontinued operations of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Operating income of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Total revenue of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Non-controlling/minority interest of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Income Statement – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Earnings and Revenue – TRADEGATE:M5E - TradingView
Free float of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Agomab closes $200 million IPO on NASDAQ - Investing.com India
Agomab closes $200 million IPO on NASDAQ By Investing.com - Investing.com Nigeria
Agomab Announces Closing of Initial Public Offering - Benzinga
EQT Life Sciences-Backed AgomAb Falls After $200 Million IPO - Mint
Agomab Therapeutics opens below IPO price in Nasdaq debut By Investing.com - Investing.com Canada
Agomab prices IPO at $16 per share, aims to raise $200 million - Investing.com Australia
Agomab prices IPO at $16 per share, aims to raise $200 million By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Agomab Therapeutics Nv Adr (AGMB) 財務データ
Agomab Therapeutics Nv Adr (AGMB) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):